Trailing-twelve-month (TTM) revenue is $55.63 Billion with a year-over-year growth of +0.81%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-29 | $14,358,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-27 |
| Q4 FY2025Period ended 2025-12-31 | $13,334,986,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q1 FY2026Period ended 2026-03-31 | $13,524,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $14,417,876,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-21 |
| TTM revenue | $55,634,862,000 |
Current P/S: $268,000,792,440 market capitalization ÷ $55,634,862,000 TTM revenue = 4.82x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $14.42B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T20:31:00.878Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD |
|---|---|---|---|---|---|
| Anti Infectives sold under Sandoz name | N/A | $784M | $694M | $707M | $777M |
| COPD | N/A | $427M | N/A | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD |
|---|---|---|---|---|---|
| CHINA | N/A | N/A | $2.6B | $3.1B | $3.1B |
| Country of domicile | $852M | N/A | $800M | $873M | $970M |
| FRANCE |
$55.63B
$55.63 Billion
+0.81%
vs. $55.19B a year ago (TTM)
+1.53%
5 Year compound annual growth rate
1 Year
+0.81%
3 Year
+6.04%
5 Year
+1.53%
10 Year
+1.12%
15 Year
(0.12%)
20 Year
+2.51%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $54.81B | +$3.09B | +5.97% |
| 2024 | $51.72B | +$5.06B | +10.85% |
| 2023 | $46.66B | +$3.20B | +7.36% |
| 2022 | $43.46B | ($513.00M) | (1.17%) |
| 2021 | $43.97B | ($5.92B) | (11.87%) |
| 2020 |
TTM Growth
+0.81%
3-Year CAGR
+6.04%
5-Year CAGR
+1.53%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-02T20:31:00.878Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| Rest of portfolio | $7.9B | $9.1B | $9.1B | $9.3B | $9.2B |
|---|
| Top 20 products | $26.9B | $28.6B | $29.9B | $32.7B | $32.1B |
|---|
| Total anti-infectives net sales | N/A | N/A | N/A | $1.1B | $1.2B |
|---|
| $2.7B |
| $2.4B |
| $2.4B |
| $2.5B |
| $2.3B |
| GERMANY | $4.2B | $4.1B | $4.5B | $4.9B | $4.3B |
|---|
| JAPAN | $3.2B | $2.7B | $2.8B | $2.7B | $2.2B |
|---|
| Other countries | $22.2B | N/A | $19.0B | $20.8B | $20.1B |
|---|
| UNITED STATES | $17.6B | $16.3B | $16.5B | $16.8B | $17.7B |
|---|
| $49.90B |
| +$1.22B |
| +2.51% |
| 2019 | $48.68B | +$2.58B | +5.59% |
| 2018 | $46.10B | +$2.69B | +6.21% |
| 2017 | $43.40B | ($6.03B) | (12.20%) |
| 2016 | $49.44B | ($951.00M) | (1.89%) |
